DPP-4 inhibitor is expected to strive against SGLT-2 inhibitor in earnest in type 2 diabetes drug market from next month

Published: 2014-08-19 10:21:08

Updated: 2014-08-19 10:21:08

DPP-4 inhibitor is expected to strive against SGLT-2 inhibitor in earnest in type 2 diabetes drug market from next month. Ministry of Health and Welfare preannounced administrative notice of 'Details about the applicable standard and method of medical care benefit (drug)' which include changes of general rule on standard of medical care benefits of diabetes treatment.

In this general rule on s...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.